Form 4: BIODESIX Officer Sells Shares for Tax, RSUs Vest

BIODESIX Chief Accounting Officer Chris Vazquez reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Chris Vazquez, Chief Accounting Officer of BIODESIX INC, reported transactions on November 10, 2025.
• Vazquez acquired 31 shares of Common Stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 13 shares of Common Stock were sold at $7.62 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Vazquez beneficially owns 936 shares of Common Stock and 29 Restricted Stock Units.
• All reported numbers reflect a one-for-twenty reverse stock split effective September 15, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: This is a routine insider transaction involving RSU vesting and a tax-related share sale, indicating ongoing executive compensation and retention, which is generally neutral to slightly positive.

Positives

• Vesting of 31 Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.

Negatives

• Sale of 13 shares of Common Stock, though for tax purposes, reduces the officer's direct equity holding.

Future Outlook

Restricted Stock Units continue to vest in sixteen successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but also a sign of executive retention and standard compensation practices.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Remaining Restricted Stock Units will continue to vest in quarterly installments, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of Restricted Stock Units (RSUs) and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives and typically do not signal a change in the company's fundamental outlook or warrant a significant shift in investment strategy. The transaction was also conducted under a Rule 10b5-1 plan, further indicating its pre-planned and non-discretionary nature. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present new information to alter an existing investment thesis.

Keywords

BIODESIX, BDSX, Form 4, insider transaction, stock sale, RSU vesting, executive compensation, Chris Vazquez, Chief Accounting Officer, Rule 10b5-1